Topiramate
- Generic Name
- Topiramate
- Brand Names
- Eprontia, Qsymia, Qudexy, Topamax, Trokendi
- Drug Type
- Small Molecule
- Chemical Formula
- C12H21NO8S
- CAS Number
- 97240-79-4
- Unique Ingredient Identifier
- 0H73WJJ391
- Background
Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines. It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults. Since 2012, the extended-release formulation has been approved in combination with phentermine for chronic weight management therapy in adults.
...
- Indication
Topiramate is indicated for the following conditions: 1)Monotherapy for partial onset or primary generalized tonic-clonic seizures for patients 2 years of age and above 2)Adjunctive therapy for partial onset seizures or primary generalized tonic-clonic seizures for both adult and pediatric patients above 2 years old 3)Adjunctive therapy for seizures associat...
- Associated Conditions
- Alcohol Dependency, Epilepsy, Primary Generalized Tonic-Clonic Seizures, Generalized Tonic-Clonic Seizures, Lennox-Gastaut Syndrome, Migraine, Moods Disorders, Partial-Onset Seizures, Seizures, Weight
- Associated Therapies
- Chronic Weight Management therapy, Weight Reduction
The Effectiveness and Safety of Topiramate on Prevention of Chronic Migraine
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-02-01
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 59
- Registration Number
- NCT00216606
Safety and Efficacy of Topamax Versus Carbamazepine in Benign Rolandic Epilepsy
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-02-01
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 114
- Registration Number
- NCT00216567
The Prolonged Use of Topiramate for Preventing Migraine Headaches
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 834
- Registration Number
- NCT00216619
An Open Label Extension of a Study Comparing Topiramate and Amitriptyline in Migraine Prevention.
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-06-10
- Target Recruit Count
- 142
- Registration Number
- NCT00210860
An Open Label Extension of a Study of Topiramate in Chronic Migraine.
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-06-10
- Target Recruit Count
- 200
- Registration Number
- NCT00210873
A Pilot Study of Topiramate in Childhood Absence Epilepsy
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-06-10
- Target Recruit Count
- 12
- Registration Number
- NCT00210574
A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-06-10
- Target Recruit Count
- 407
- Registration Number
- NCT00210808
Comparing the Safety and Effectiveness of Topiramate With the Safety and Effectiveness of Amitriptyline in Preventing Migraine Headaches
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-06-10
- Target Recruit Count
- 347
- Registration Number
- NCT00210821
An Efficacy and Safety Study of Topiramate in the Treatment of Alcohol Dependence
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-06-08
- Target Recruit Count
- 371
- Registration Number
- NCT00210925
Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache.
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Ortho-McNeil Neurologics, Inc.
- Target Recruit Count
- 385
- Registration Number
- NCT00212810
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.